Molecular Templates and Takeda jointly develop CD38-targeted engineering toxins

recently,, a U.Sbio
company, announced a partnership agreement with TakedaPharmaceutical
to jointly develop CD38-targeted engineered toxin bodies ( ETBs) for the treatment of diseases including multiple myelomathe company's current CD38-led CD38 target ing-
drug(the result of previous collaborations between the two companies)the two sides conducted preclinical studies of CD38 targeting ETBs through previous research collaborationsThis time, Takeda and Molecular Templates will further develop ETBs for the treatment of multiple myeloma under this new licensing, development and commercialization agreementunder the terms of the agreement, Takeda will pay $30 million in advance and be eligible for up to $632.5 million in development, regulatory and commercialization milestone payments if Molecular Templates exercises its joint development options, and $337.5 million if the joint development option is not exercised or opted outTakeda also agreed to pay royalties for the sale of commercialproductsthrough co-developmentMolecular Templates and Takeda will share the development costs equallybecause of the widespread expression of CD38 protein in multiple myeloma cells, CD38 has become an important target for the treatment of this cancer CD38-targeted ETBs identify proteins and transmit a modified bacterial toxin into myeloma cells, killing these cancer cells through enzymatic and ribosome irreversible destruction Unlike other CD38 targeted therapies, ETBs do not depend on their own immune systems, which provides a broader and deeper potential for disease mitigation